PPT-Statin Landmark Trials Across the Spectrum of Risk: Seconda

Author : celsa-spraggs | Published Date : 2016-07-03

TNT Study Design Treating to New Targets 2 5 years 10001 Patients Clinically evident CHD LDLC 130 250 mgdL following up to 8week washout and 8week openlabel

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Statin Landmark Trials Across the Spectr..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Statin Landmark Trials Across the Spectrum of Risk: Seconda: Transcript

TNT Study Design Treating to New Targets 2 5 years 10001 Patients Clinically evident CHD LDLC 130 250 mgdL following up to 8week washout and 8week openlabel runin with atorvastatin. Implications from the SHARP trial. Dr. Christina Reith. University . of. Oxford. United . Kingdom. Outline of presentation . Lowering LDL cholesterol in non-renal patients. Lowering LDL cholesterol in renal disease. Dyslipidemia. . Treatment. USA-145-101385. © . 2014 . Amgen Inc. All rights reserved. Not for Reproduction. . Table of Contents. Dyslipidemia. Dyslipidemia in . Diabetes. Dyslipidemia in Familial Hypercholesterolemia. Under-Representation of Women . in Clinical Trials. CVD in Women. Women. ’. s CV Risk is Often Misunderstood or Misdiagnosed. Gender Disparities in Screening, Diagnosis, and Treatment of Dyslipidemia. Optimizing . patient care. William Cromwell, MD, FAHA, FNLA. Chief Medical Officer – LipoScience, Inc.. Chief – Lipoprotein and Metabolic Disorders Institute. Adjunct Associate Professor – Wake Forest University School of Medicine. , MD. Acute Respiratory Failure. CAUSES- Anatomic Approach. . i. ) Airway . . . ii) Parenchymal. . . iii) Vascular. . . iv) Pleural. . . v) Neuro-muscular. vi) MULTIFACTORIAL. . . Dr. . M. anju Banerjee . VP and Director, LCIRT . Landmark College . manjubanerjee@landmark.edu. Jeffrey J. Nolan, J.D.. Dinse, Knapp & McAndrew, P.C.. www.dinse.com. . . Agenda. ADA Definitions. Purpose. Outline highlights from the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol. Review statin management in high risk patients. 2. ACC/AHA 2018: Overall Approach. Assess risk, determine management group. Beauty is in the Eye of the Beholder. Brian Asbill, MD. Asheville Cardiology Associates. Overview. NHLBI, ACC, AHA expert panel convened 2008. First new guidelines since ATP III guideline update in . cross . the . spectrum . of . risk. : . Secondary . stroke . p. revention. . (N=488). Simvastatin. in Patients With Prior . Cerebrovascular. Disease: HPS. *29% RRR, . p. =0.001. Heart Protection Study Collaborative Group. . Evidence from . meta-analyses of . Mendelian. . randomization. studies. , . prospective. cohort studies. , . and. . randomized. . controlled. trials . unequivocally establishes that LDL causes ASCVD. Control. Relative risk. Absolute Effect. (per thousand). Statin. Myalgia. 348/14960. (2.3%) . 288/14520. (2.0%). 1.02. (0.88-1.19). +1. (-1 to +5). Rhabdomyolysis. 138/2454. (5.6%). 158/2446. (6.5%). to Reduce Atherosclerotic Cardiovascular . Risk in Adults . 2013 ACC/AHA Guideline on. O. verview. RCTs indicated a constant reduction of ASCVD by . statins. in 1ry & 2ry prevention.. No event reduction. of. Dyslipidemia. Navid Saadat, MD. Associate Professor of Endocrinology. Shahid Beheshti University of Medical Sciences. Rationale for . Treatment. Benefit . of . LDL-C. . reduction in . CVD events. Risk Assessment and Cholesterol Management. Roger S. Blumenthal, MD. The Kenneth Jay . Pollin. Professor of Cardiology. Director, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease.

Download Document

Here is the link to download the presentation.
"Statin Landmark Trials Across the Spectrum of Risk: Seconda"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.